Comparative Pharmacology
Head-to-head clinical analysis: REBIF versus TERIFLUNOMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REBIF versus TERIFLUNOMIDE.
REBIF vs TERIFLUNOMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Interferon beta-1a binds to type I interferon receptors, activating the JAK-STAT signaling pathway, which leads to expression of interferon-responsive genes. This results in modulation of immune responses, including reduction of pro-inflammatory cytokines, enhancement of anti-inflammatory cytokines, inhibition of T-cell activation and proliferation, and decreased blood-brain barrier permeability.
Teriflunomide inhibits dihydroorotate dehydrogenase, a key enzyme in de novo pyrimidine synthesis, thereby reducing proliferation of activated T and B lymphocytes.
Subcutaneous injection, 22 mcg (0.5 mL) or 44 mcg (0.5 mL) three times per week, at least 48 hours apart.
7 mg orally once daily with or without food.
None Documented
None Documented
Clinical Note
moderateTeriflunomide + Gatifloxacin
"Teriflunomide may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateTeriflunomide + Rosoxacin
"Teriflunomide may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateTeriflunomide + Trovafloxacin
"Teriflunomide may increase the neuroexcitatory activities of Trovafloxacin."
Clinical Note
moderateTeriflunomide + Nalidixic acid
Terminal half-life approximately 50 hours (range 28-75 hours) after subcutaneous administration, supporting every-other-day dosing.
Terminal half-life approximately 18-19 days (range 10-30 days) due to enterohepatic recirculation. Clinical context: Requires prolonged elimination (up to 2 years to reach undetectable levels) due to slow clearance; accelerated elimination with cholestyramine or activated charcoal may be needed for toxicity.
Renal (primarily via glomerular filtration and catabolism) and hepatic metabolism; <5% excreted unchanged in urine.
Primarily biliary/fecal (approximately 60% unchanged drug and metabolites in feces, 23% in urine). Renal elimination of unchanged drug is minimal (<0.5%). Enterohepatic recycling contributes to long half-life.
Category C
Category C
Immunomodulator
Immunomodulator
"Teriflunomide may increase the neuroexcitatory activities of Nalidixic acid."